Literature DB >> 11160265

Innate and adaptive immune responses to nonvascular xenografts: evidence that macrophages are direct effectors of xenograft rejection.

A Fox1, J Mountford, A Braakhuis, L C Harrison.   

Abstract

Nonvascularized xenograft rejection is T cell mediated, but is dependent on initial macrophage (Mphi) infiltration. We developed an i.p. transplant model to define the roles of Mphi and T cells in xenograft rejection. Nonobese diabetic or BALB/c mice were injected i.p. with xenogeneic, allogeneic, or syngeneic cells, and the responding cells in subsequent lavages were assessed by flow cytometry and adoptive transfer. Neutrophils and monocytes/elicited Mphi were rapidly recruited in response to xenogeneic pig (PK15 or spleen) cells and, to a significantly lesser extent, allogeneic cells. These innate responses preceded T cell infiltration and occurred in their absence in SCID mice. Syngeneic cells induced negligible neutrophil or Mphi responses. Neutrophils and Mphi induced by xenogeneic cells in SCID mice stimulated T cell recruitment after transfer to immunocompetent mice. T cells in turn were required for Mphi activation and xenogeneic cell rejection. Thus, Mphi harvested from immunocompetent but not SCID mice injected with xenogeneic cells expressed activation markers and rejected xenogeneic cells when transferred into SCID mice. These findings demonstrate the interdependent roles of Mphi and T cells in xenograft rejection. The requirement for Mphi reflects their ability to mount a rapid, local innate response that stimulates T cell recruitment and, having received T cell help, to act as direct effectors of rejection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160265     DOI: 10.4049/jimmunol.166.3.2133

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

Review 1.  CD47 in xenograft rejection and tolerance induction.

Authors:  Yong-Guang Yang
Journal:  Xenotransplantation       Date:  2010 Jul-Aug       Impact factor: 3.907

2.  [Renal cell carcinoma associated proteins. Isolation, cloning and immunogenicity evaluation].

Authors:  A Haferkamp; M Hohenfellner; R Hautmann; M Zöller
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

Review 3.  The innate immune system in transplantation.

Authors:  Martin H Oberbarnscheidt; Daniel Zecher; Fadi G Lakkis
Journal:  Semin Immunol       Date:  2011-07-01       Impact factor: 11.130

4.  Non-self recognition by monocytes initiates allograft rejection.

Authors:  Martin H Oberbarnscheidt; Qiang Zeng; Qi Li; Hehua Dai; Amanda L Williams; Warren D Shlomchik; David M Rothstein; Fadi G Lakkis
Journal:  J Clin Invest       Date:  2014-07-01       Impact factor: 14.808

Review 5.  Immunological challenges and therapies in xenotransplantation.

Authors:  Marta Vadori; Emanuele Cozzi
Journal:  Cold Spring Harb Perspect Med       Date:  2014-04-01       Impact factor: 6.915

6.  Common and small molecules as the ultimate regulatory and effector mediators of antigen-specific transplantation reactions.

Authors:  Vladimir Holan; Magdalena Krulova
Journal:  World J Transplant       Date:  2013-12-24

7.  Human CD47 expression permits survival of porcine cells in immunodeficient mice that express SIRPα capable of binding to human CD47.

Authors:  Chunfeng Wang; Hui Wang; Kentaro Ide; Yuantao Wang; Nico Van Rooijen; Hideki Ohdan; Yong-Guang Yang
Journal:  Cell Transplant       Date:  2011-04-29       Impact factor: 4.064

Review 8.  Overcoming the barriers to xenotransplantation: prospects for the future.

Authors:  Burcin Ekser; David K C Cooper
Journal:  Expert Rev Clin Immunol       Date:  2010-03       Impact factor: 4.473

Review 9.  Innate allorecognition by monocytic cells and its role in graft rejection.

Authors:  F G Lakkis; X C Li
Journal:  Am J Transplant       Date:  2017-08-24       Impact factor: 8.086

Review 10.  Pancreatic islet xenotransplantation: barriers and prospects.

Authors:  Gina R Rayat; Ronald G Gill
Journal:  Curr Diab Rep       Date:  2003-08       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.